Promethera to use microfluidic system from Millipore for liver disease research
EMD Millipore, Merck KGaA's life science division, has received a US$400,000 grant from the US Massachusetts Life Sciences Center (MLSC) to fund a liver disease research partnership with Belgian pharmaceutical company Promethera Biosciences. This is one of four grants given to life science companies in Massachusetts as part of MLSC’s International Collaborative Industrial Program.
Through the partnership, EMD Millipore’s microfluidic technology will enable researchers at Promethera to mimic the liver microenvironment long-term, allowing for increased consistency and scale-up potential for live cell models. Using liver stem cells provided by Promethera and EMD Millipore’s CellASIC microfluidic cell culture platform, both companies aim to improve preclinical liver toxicity testing methods.
'The opportunity to work closely with Promethera over the course of the project speaks to the nature of our organisation: enabling our partners to conduct potentially life-saving research,' said Robert Yates, President and CEO of EMD Millipore. 'We are looking forward to building our relationship and more importantly to the outcomes this partnership has the potential to deliver.'